眼压或垂直杯盘比多基因风险评分的预测能力
这项遗传关联研究在加拿大老龄化纵向研究(CLSA)和Busselton健康老龄化研究(BHAS)中构建并评估了眼压(IOP)与垂直杯盘比(VCDR)的多基因风险评分(PRS),并在英国生物样本库中验证。VCDR PRS在CLSA和BHAS中分别解释22.0%和19.7%的表型方差,IOP PRS分别解释12.9%和9.6%。作者认为高VCDR PRS个体即使眼压正常也可能有青光眼风险,有助于早期检测和干预。
要点
- VCDR PRS在CLSA和BHAS中分别解释22.0%和19.7%的VCDR表型方差。
- IOP PRS在CLSA和BHAS中分别解释12.9%和9.6%的IOP表型方差。
- 高VCDR PRS个体即使眼压处于正常范围也可能有青光眼风险。
核心结论
- 基于近期发表的大型多性状全基因组关联研究(GWAS)构建的VCDR和IOP PRS在独立队列中表现出有效性。
- 作者认为IOP PRS有潜力识别可能受益于更强化降眼压治疗的个体。
- 作者认为高VCDR PRS个体即使眼压测量值在正常范围内也可能有发生青光眼的风险,提示这些PRS有助于早期检测和干预。
研究设计与样本
- 遗传关联研究,评估CLSA中51338人里的6959人和BHAS中5107人里的4960人的PRS。
- CLSA数据来自加拿大11个中心,时间为2010年至2015年;BHAS为社区研究,地点为西澳大利亚Busselton,时间为2010年至2015年。
- 使用人工智能分级方法获得CLSA数据集的精确VCDR估计值。
- 使用英国生物样本库约500000人2006年至2010年的数据验证PRS效力。
- 数据分析时间为2023年6月至11月。
主要发现
- VCDR PRS在CLSA中解释22.0%(95%CI 20.1-23.9)的VCDR表型方差,在BHAS中解释19.7%(95%CI 16.3-23.3)。
- IOP PRS在CLSA中解释12.9%(95%CI 11.3-14.6)的IOP表型方差,在BHAS中解释9.6%(95%CI 8.1-11.2)。
- 在非洲、东亚和南亚人群中,VCDR PRS解释的方差分别为5.2%(95%CI 3.6-7.1)、12.1%(95%CI 7.5-17.5)和14.3%(95%CI 9.3-19.9)。
- 在非洲、东亚和南亚人群中,IOP PRS解释的方差分别为2.3%(95%CI 1.5-3.3)、3.2%(95%CI 1.3-5.8)和7.5%(95%CI 6.2-8.9)(P < .001)。
临床怎么用
- 作者认为IOP PRS有潜力识别可能受益于更强化降眼压治疗的个体。
- 作者认为高VCDR PRS个体即使眼压测量值在正常范围内也可能有发生青光眼的风险,这些PRS可能有助于早期检测和干预,尤其是在仅基于眼压可能被考虑为低风险的人群中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Early detection of glaucoma is essential to timely monitoring and treatment, and primary open-angle glaucoma risk can be assessed by measuring intraocular pressure (IOP) or optic nerve head vertical cup-disc ratio (VCDR). Polygenic risk scores (PRSs) could provide a link between genetic effects estimated from genome-wide association studies (GWASs) and clinical applications to provide estimates of an individual's genetic risk by combining many identified variants into a score. OBJECTIVE: To construct IOP and VCDR PRSs with clinically relevant predictive power. DESIGN, SETTING, AND PARTICIPANTS: This genetic association study evaluated the PRSs for 6959 of 51 338 individuals in the Canadian Longitudinal Study on Aging (CLSA; 2010 to 2015 with data from 11 centers in Canada) and 4960 of 5107 individuals the community-based Busselton Healthy Aging Study (BHAS; 2010 to 2015 in Busselton, Western Australia) with an artificial intelligence grading approach used to obtain precise VCDR estimates for the CLSA dataset. Data for approximately 500 000 individuals in UK Biobank from 2006 to 2010 were used to validate the power of the PRS. Data were analyzed from June to November 2023. MAIN OUTCOMES AND MEASURES: IOP and VCDR PRSs and phenotypic variance (R2) explained by each PRS. RESULTS: Participants in CLSA were aged 45 to 85 years; those in BHAS, 46 to 64 years; and those in UK Biobank, 40 to 69 years. The VCDR PRS explained 22.0% (95% CI, 20.1-23.9) and 19.7% (95% CI, 16.3-23.3) of the phenotypic variance in VCDR in CLSA and BHAS, respectively, while the IOP PRS explained 12.9% (95% CI, 11.3-14.6) and 9.6% (95% CI, 8.1-11.2) of phenotypic variance in CLSA and BHAS IOP measurements. The VCDR PRS variance explained 5.2% (95% CI, 3.6-7.1), 12.1% (95% CI, 7.5-17.5), and 14.3% (95% CI, 9.3-19.9), and the IOP PRS variance explained 2.3% (95% CI, 1.5-3.3), 3.2% (95% CI, 1.3-5.8), and 7.5% (95% CI, 6.2-8.9) (P < .001) across African, East Asian, and South Asian populations, respectively. CONCLUSIONS AND RELEVANCE: VCDR and IOP PRSs derived using a large recently published multitrait GWAS exhibited validity across independent cohorts. The findings suggest that an IOP PRS has the potential to identify individuals who may benefit from more intensive IOP-lowering treatments, which could be crucial in managing glaucoma risk more effectively. Individuals with a high VCDR PRS may be at risk of developing glaucoma even if their IOP measures fall within the normal range, suggesting that these PRSs could help in early detection and intervention, particularly among those who might otherwise be considered at low risk based on IOP alone.
引用
- He W, Lee SS, Diaz Torres S, et al. Predictive Power of Polygenic Risk Scores for Intraocular Pressure or Vertical Cup-Disc Ratio. JAMA Ophthalmol. 2025. PMID: 39570582. doi:10.1001/jamaophthalmol.2024.4856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。